This is a new guideline from NICE advising that we can use fremanezumab for preventing migraine in selected populations. It was published in June 2020.
It can be used if:
- the migraine is chronic ie 15 or more headache days each month for at least 3 months, with at least 8 of those days having features of migraine AND
- at least three preventative drugs have failed AND
- it is provided according to the commercial agreements with the company.
It should be stopped if it does not reduce migraine frequency by 30% after 12 weeks of treatment.